Signs of more amicable agreements over patent disputes in Russia

Global drugmakers may find it easier to reach amicable agreements with their Russian rivals over patent disputes for their drugs in the local market, mainly due to a recent agreement, reached between Russian drugmaker Pharmasyntez and the Argentinean firm Laboratorio Tuteur in the patent dispute between the companies.

On July 12, the Arbitration Court of St Petersburg discontinued its proceedings of a case, initiated by Tuteur against Pharmasyntez a while ago, report The Pharma Letter’s local correspondent.

In its initial judicial complaint, the Argentinean company asked the court to ban Pharmasyntez from a further manufacture and sales of the anticancer drug capecitabine, as this violates exclusive rights of Tuteur, being a generic of an original drug, produced by the Argentinean company.